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Synthesis, biological activity and NMR-based structural studies of deltorphin I analogues modified 
in message domain with a new α,α-disubstituted glycines† 
 
Anika Lasotaa, Oliwia Frączaka, Adriana Muchowskab, Michał Nowakowskic, Maciej Maciejczykd, 
Andrzej Ejcharte, Aleksandra Olmaa* 
 
 
 
 
 
 
 
Eight new analogues of DTI were designed, synthesized and 
tested for receptor affinity and selectivity to μ- and δ-opioid 
receptors. NMR solution structure of μ-selective Tyr-D-Ala-
(S)-α-benzyl-β-(1-piperidinyl)Ala-Asp-Val-Val-Gly-NH2 and δ-
selective Tyr-D-Ala-(R)-α-benzyl-β-(1-piperidinyl)Ala-Asp-Val-
Val-Gly-NH2 were determined and diussed. 
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Synthesis, biological activity and NMR-based structural studies of deltorphin I 
analogues modified in message domain with a new α,α-disubstituted glycines† 
Anika Lasotaa, Oliwia Frączaka, Adriana Muchowskab, Michał Nowakowskic, Maciej 
Maciejczykd, Andrzej Ejcharte, Aleksandra Olmaa* 
a Institute of Organic Chemistry, Lodz University of Technology, Żeromskiego 116, 90-924 
Lodz, Poland  
bMossakowski Medical Research Centre, Polish Academy of Sciences, Pawińskiego 5, 01-793 
Warsaw, Poland 
c Centre of New Technologies, University of Warsaw, Banacha 2C, 02-097 Warsaw, Poland  
d
 Department of Physics and Biophysics, Faculty of Food Science, University of Warmia and 
Mazury, Oczapowskiego 4, 10-719 Olsztyn, Poland  
e Institute of Biochemistry and Biophysics, Polish Academy of Sciences, Pawińskiego 5A, 02-
106 Warsaw, Poland 
† This paper is dedicated to the memory of Andrzej Lipkowski (deceased November 27, 
2014). The peptide community has lost an excellent scientist and a dear friend, and he will be 
missed by all of us who were fortunate enough to know him and work with him.  
 
Abstract: 
This paper describes new deltorphin I analogues in which phenylalanine residues were 
replaced by the corresponding (R) or (S)-α-benzyl-β-azido(1-pyrrolidinyl, 1-piperidinyl, 4-
morpholinyl)alanine residues. All analogues were tested for receptor affinity and selectivity to 
µ- and δ-opioid receptors. The affinity of analogues containing (R) or (S)-α-benzyl-β-
azidoalanine in position 3 to δ-receptors strongly depended on the chirality of the α,α-
disubstituted residue. The conformational behavior of peptides modified with (R) or (S)-α-
benzyl-β-(1-piperidinyl)Ala, which display the opposite selectivity, was analyzed by 1H and 
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13C NMR. The µ-selective Tyr-D-Ala-(R)-α-benzyl-β-(1-piperidinyl)Ala-Asp-Val-Val-Gly-
NH2 lacks the helical conformation observed in the δ-selective Tyr-D-Ala-(S)-α-benzyl-β-(1-
piperidinyl)Ala-Asp-Val-Val-Gly-NH2. Our results support the proposal that differences 
between δ- and µ-selective opioid peptides are attributable to the presence or absence of a 
spatial overlap between the N-terminal message domain and the C-terminal address domain. 
 
INTRODUCTION 
 
Opioid peptides include a large group of physiologically active bioregulators exhibiting a 
broad spectrum of biological activity and interacting with opioid receptors (µ, δ, κ). 
Deltorphins are heptapeptides that have been isolated from the South American frog 
belonging to the genus Phyllomedusa (1). Deltorphins show a higher affinity and selectivity 
for δ opioid receptors than any other endogenous mammalian compound (2).  
Deltorphin I and deltorphin II consist of two parts, a biologically important N-terminal 
tripeptide fragment (Tyr-D-Ala-Phe, the message domain), a binding pharmacophore (3), and 
a C-terminal fragment (Asp/Glu-Val-Val-Gly-NH2, the address domain). Anionic and 
hydrophobic C-terminal tetrapeptides decrease µ affinity while at the same time increasing δ 
affinity (4). The conformational, topographical and stereoelectronic structural features of the 
opioid peptides are important for interaction with µ, δ, and κ opioid receptors. Two aromatic 
amino acids, Tyr1 and Phe3 or Phe4, are important structural elements because they interact 
with opioid receptors. The search for new analogues of deltorphins is an important direction 
of study because they are likely to be effective analgesic agents for the treatment of cancer 
pain (5) and neuropathic pain (6) with a low potential for abuse (7,8). Since the discovery of 
endogenous amphibian peptides hundreds of analogues of the various deltorphins have been 
synthesized (9). 
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It has been proposed that the δ-receptor selectivity of deltorphins is a result of the formation 
of special nonequal amphiphilic topography (‘hot-dog’ shape) (3). In such a conformation, the 
hydrophilic strain (‘hot-dog’) formed by ionic and hydrogen bonds between NH2 (Tyr1)...- 
COOH(Asp4)...CONH2 (Gly7) is surrounded by dominating lipophilic shells (‘hot-dog roll’). 
Some very potent and selective cyclic analogues, which stabilized this conformation, have 
supported the proposed model (10). The incorporation amphiphilic amino acid residues (α-
hydroxymethylphenylalanine) also support proposed molecular models of the active 
conformation of deltorphins (11). 
The presented paper describes the synthesis and receptor binding of new analogues in which 
Phe3 residue in the deltorphin I sequence was substituted by (R) or (S)-α-benzyl-β-azido(1-
piperidinyl, 1-pyrrolidinyl, 4-morpholinyl)alanine (Figure 1). Phenylalanine in position 3 of 
δ-selective deltorphins and µ-selective dermorphin plays a key role in binding and 
discrimination between δ and µ opioid receptors. 
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Figure 1. Structure of new deltorphin I analogues  
Optically pure α,α-disubstituted glycines were obtained from available N-Boc-(R or S)-α-
benzylserine β-lactone (12). The treatment of N-Boc-(R or S)-α-benzylserine β-lactone with 
sodium azide or free heterocyclic amines (pyrrolidine, piperidine, morpholine) as nucleophile 
gives suitable, enantiomerically pure N-Boc-(R or S)-α-benzyl-β-azido(sec-amino)alanines 
(13). 
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The β-azido group is an effective C7-conformation-directing element, which may be useful 
for tuning the structures of other amino acids and polypeptides. However, it has not been 
clarified yet whether the azido group can induce any conformational change via 
stereoelectronic effects when introduced into the β-carbon of alanine (14). 
 
Experimental Section 
Chemistry 
Most chemicals were purchased from Sigma-Aldrich and used as received without further 
purification. All untreated solvents used were of HPLC grade. Fluorenylmethyloxycarbonyl 
(Fmoc)-protected amino acids and Fmoc-Rink Amide AM Resin were purchased from 
IrisBiotech (Marktredwitz, Germany). (R) and (S) N-Boc-α-benzyl-β-azido(sec-amino) 
alanines were obtained according to a procedure described in the literature (12,13). All 
solvents and reagents used for solid-phase synthesis were of analytical quality and used 
without further purification. Thin layer chromatography (TLC) was performed on UV plates 
(Fluka Analytical, Silica on TLC Alufoils, with a 254 nm fluorescent indicator). The coupling 
reagents HATU and HOAt were purchased from AK Scientific, Inc. (CA, USA). All other 
reagents and solvents were of analytical or HPLC grade and were bought from Sigma Aldrich 
(Poland) or Avantor Performance Materials Poland S.A. 
Analytical reverse-phase HPLC was performed on a GraceSmart C18 column (Grace, 4.6 mm 
× 250 mm, 5 µm), flow rate 1.0 mL/min, detection at 220 nm, solvents (A) 0.05% 
trifluoroacetic acid (TFA) in water and (B) 0.038% TFA in acetonitrile/water 90:10 in linear 
gradient elution. The final peptides were purified by RP HPLC on a Thermoseparation 
Products P400 Spectra System (detection at 220 nm) using a Gemini C18 column 
(Phenomenex, 250 mm × 10 mm, 10 µm), flow rate 3.0 mL/min. 
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1H NMR spectra of protected amino acids, di- and tripeptides were recorded on a Bruker DPX 
250 spectrometer (Bruker Biospin GMBH, Rheinstetten, Germany). Proton chemical shifts 
are reported in ppm (d) relative to internal tetramethylsilane (TMS, d: 0.00). Data are reported 
as follows: chemical shift {multiplicity [singlet (s), doublet (d), triplet (t), quartet (q), and 
multiplet (m)], coupling constants [Hz], integration}. ESI-LC-MS was recorded on a Bruker 
amaZon speed ETD trap, with an ESI ion source, positive ion polarity, a maximum resolution 
mass range, and a 50–2000 m/z range. 
General procedure for synthesis of 2a-2c 
To N-Boc-(R or S)-α-benzyl-β-azido(sec-amino)alanine (1,2 mM) in 3 ml of MeOH, a freshly 
prepared ethereal solution of diazomethane was added until the yellow color of diazomethane 
persisted. Reaction without stirring was left overnight. The progress of the reactions was 
monitored with TLC (chloroform:methanol 9:1 v/v). Then 99.5 % acetic acid was added 
carefully to destroy unreacted diazomethane and the solvents are removed under vacuum on a 
rotary evaporator. The crude methyl ester was diluted with ethyl acetate (25 ml) and washed 
with three portions of water, 5% NaHCO3, and brine, dried with magnesium sulfate, and 
concentrated under vacuum. N-Boc-(R or S)-α-benzyl-β-azidoalanines without further 
purification were used in the next step, N-Boc-(R or S)-α-benzyl-β-(sec-amino)AlaOMe were 
purified by flash chromatography (chloroform: methanol 95:5 v/v). 
General Procedure for the deprotection of the Boc-group 
To a solution of N-Boc-(R or S)-α-benzyl-β-azido(sec-amino)AlaOMe in 1 ml of ethyl acetate 
7 ml of 2 N HCl in AcOEt was added. After 2 hours next portion of 7 ml HCl in AcOEt was 
added and the stirring was continued for 2-4 hours. The reaction was monitored by TLC 
(chloroform: methanol 9:1 v/v). After conversion of all starting material the product was 
precipitated with diethyl ether. Precipitated amorphous solids were filtered off and washed 
with ethyl ether and used for the next step without further purification. 
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General procedure for synthesis 3a-3d and 4a-4d 
To a stirred solution of Boc-D-alanine or N,O-DiBoc-tyrosine (1eq.) in dry DCM, HATU 
(1eq), HOAt (1 eq) and N-methylmorpholine (4 eq for monohydrochlorides, or 5 eq for 
dihydrochlorides) were added. After 20 min. methyl ester hydrochloride of amino acid 2a-2d 
or hydrochloride of unprotected dipeptide 3a-3d (1 eq) dissolved in 2 ml of dry 
dimethylformamide was added. The reaction progress was controlled by TLC in chloroform: 
methanol 9:1 v/v. After 20 hours, if a significant amount of unreacted substrates were present, 
additional amount of HATU(0.5 eq) and HOAt (0.5 eq) and amine (1 eq) were added. Then, 
the reaction mixture was stirred at room temperature for 16 h. The solvent was evaporated 
under reduced pressure; the residue was diluted with ethyl acetate and washed with three 
portions of water, 1 N NaHSO4 (for dipeptides containing secondary amines this step was 
omitted due to formation of quaternary ammonium salts), 5% NaHCO3, and brine, dried with 
magnesium sulfate, and concentrated under vacuum. Purification by flash chromatography 
(chloroform:methanol 95:5v/v) afforded the desired di- or tripeptides.  
General procedure for synthesis of 5a-5d 
To the solution of 4a-4d (1 mM) in 5 ml of methanol cooled in an ice bath 3 ml of 1 N NaOH 
was added. Stirring was continued at room temperature until no starting material remained (3 
to 6 hours, TLC chloroform: methanol 9:1 v/v). Then the methanol was evaporated under 
reduced pressure at room temperature. The residue was diluted with 20 ml of water and the 
aqueous layer was washed with diethyl ether (3x10 ml) and acidified with 1N NaHSO4 to 
pH≈2-3 (analogs containing an azido group) or pH≈6-7 (analogues containing a sec-amino 
group). Then aqueous layer was saturated with NaCl and extracted with ethyl acetate (3x15 
ml). The combined ethyl acetate layer was dried over MgSO4, and evaporated in vacuo. The 
crude N-protected tripeptides (5a-5d) were used for the next step. 
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The structures of all isolated compounds were established by nuclear magnetic resonance 
(NMR). Full characterization as well as detailed experimental procedures for all intermediates 
is is available in the online supporting information. 
General procedure for synthesis of I-VIII 
Tetrapeptide resin was prepared by the manual solid-phase technique on Rink-amide AM 
resin (capacity 0.1 mmol/g), according to standard methods for peptides synthesized by the 
Fmoc/tBu strategy. The protected amino acids were coupled with a 3-fold excess using TBTU 
as a coupling reagent in the presence of HOBt and DIPEA in DCM. In the case of a positive 
Kaiser test (15), the coupling was repeated with a 1.5 fold excess of reagents. The Fmoc 
groups were removed by treatment with 20% piperidine in DMF. The tetrapeptide on resin 
was acylated with a 2-fold excess of N,O-protected tripeptides containing (R) or (S)-α-benzyl-
β-azido(sec-amino)alanine 5a-5d using HATU as a coupling reagent in the presence of HOAt 
and DIPEA in DCM. In the case of a positive Kaiser test, the coupling was repeated with a 
1.2 fold excess of reagents. The heptapeptides were cleaved from the resin and protecting 
groups were removed in one step using a mixture of TFA/H2O (95:5 by vol) (20 ml/100mg of 
peptide resin, 3.5 h at room temperature). The acid solution was concentrated in vacuo, and 
the crude peptides were dissolved in water/t-butanol (1:1 by vol), lyophilized and then 
purified by RP-HPLC. All heptapeptides were characterized by analytical RP-HPLC and 
molecular weight determination. 
Ligand binding assay 
Receptor binding assays were performed as described previously (11). Rat membrane 
preparation followed the procedure described by Misicka et al. (3) The radioligand receptor 
binding protocol was based on a study performed by and Fichna et al. (16) with some 
modifications. The modification included different incubation time (60min. vs. 120min), 
bacitracin concentration (30 µg/ml vs. 50 µg/ml) and radioligand choice. The modifications 
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were implemented in order to obtain optimal binding conditions. Binding affinities for µ- and 
δ-opioid receptors were determined by displacing [3H]-DAMGO and [3H]-DELT respectively, 
from adult male Wistar rat brain membrane binding sites. Binding curves were fitted using 
nonlinear regression. Compound potency was expressed as IC50 values (Table 1). 
NMR experiments and computation of peptide structures 
NMR samples with a volume of 650 µL contained 5mg of Tyr-D-Ala-(S)-α-benzyl-β-(1-
piperidinyl)Ala-Asp-Val-Val-Gly-NH2 (V) or 4 mg Tyr-D-Ala-(R)-α-benzyl-β-(1-
piperidinyl)Ala-Asp-Val-Val-Gly-NH2 (VI) dissolved in a H2O/D2O mixture (90:10 by vol). 
All spectra were measured on an Agilent DDR2 spectrometer operating at 600 MHz 
resonance frequency (1H), 60.8 MHz (15N), and 150.9 MHz (13C) at temperature 25°C. 
Temperature calibration was carefully adjusted using an ethylene glycol reference sample 
(17). 2D Homonuclear TOCSY (18) (mixing time 80 ms), ROESY (19) (mixing time 300 ms) 
and heteronuclear 1H/15N HSQC (20) and 1H/13C HSQC (with the offset, spectral widths, and 
13C−1H coupling constants tuned to either aliphatic or aromatic carbons) spectra were used to 
obtain assignments of the 1H, 15N and 13C resonances. Time domain data were acquired using 
States-TPPI quadrature detection (21). Water suppression was achieved with pulsed field 
gradients echo (22). All chemical shifts in 1H NMR spectra were reported with respect to 
external DSS-d4. Chemical shifts of 13C and 15N signals were referenced indirectly using the 
0.251449530 and 0.101329118 frequency ratios 13C/1H and 15N/1H respectively (23). Zero 
filling and a 90º-shifted squared sine-bell filter were performed prior to Fourier 
transformation. Processed spectra were analyzed with SPARKY software (24). 
Intensities of interproton correlations in ROESY spectra, Iij, were used in determining 
appropriate distances rij from the equation Iij = C⋅rij-6 (25). The constant C was calculated from 
the intensity of correlation between tyrosine protons HD and HE of fixed distance assumed to 
be equal to 2.48 Å in case of V. In case of VI correlation intensities between tyrosine protons 
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HA and both HB were used assuming r = 2.5 Å for stronger correlation and r = 3 Å for a 
weaker one. 
Calibration 
Parametrization of modified residues 
For all natural amino-acid residues standard Amber ff10 force-field parameters were applied 
(26). The parametrization of α-benzylo-β-(1-piperydynyl)Ala residue was based on ff10 
parameters for phenylalanine residue. The piperydynyl part of amino-acid residue was 
parameterized in the following manner. Bonded part of the potential was automatically 
assigned by Antechamber and GAFF force-field (27, 28). Partial charges were determined by 
fitting them (RESP) to the electrostatic potential (29) obtained from quantum mechanical 
computations at the MP2/6-31G(d,p) level with Gaussian 03 package (30). 
Simulated annealing procedure 
The peptide chain was built with xleap program of the Amber package. In order to remove 
bad contacts 1000 steps of geometry optimization was applied with steepest-descent energy 
minimization method. The chain was heated up from 10 to 1200K in 1ps molecular dynamics 
run, followed by 2ps of high-temperature dynamics and 12ps cooling process. NMR distance 
restraints were slowly switched on during first 3ps of simulated annealing run. Improper 
dihedral restraints on chiral centers were switch on to prevent chirality flipping during the 
high-temperature dynamics. Finally the geometry of the peptide was optimized by 1000 steps 
of steepest-descent and 2000 steps of conjugate-gradient energy minimization procedure. The 
time-step of the simulation was 1fs and Generalized Born solvation model was applied (31-
33). The simulated-annealing cycle was repeated 100 times and the lowest-energy structure 
was used as the initial structure for time-averaged restrained molecular dynamics simulation. 
Time-averaged restrains MD simulation 
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The geometry of the initial structure was optimized and equilibrated in 1ns MD run with time-
averaged restraints applied. The SHAKE algorithm was used to keep covalent bonds with 
hydrogens constant and 2fs time-step was applied. The solvation effects were described by 
Generalized-Born model (31-33). During 20 ns production run proton-proton distance 
restraints obtained from NMR experiment were time-averaged over 1ps time interval. The 
average energies of time-averaged distance restraints were below 1 kcal/mol for both 
peptides. The resulting trajectories were clustered with average-linkage clustering algorithm. 
The clustering metrics was RMSD of all heavy atoms of the backbone. The number of 
clusters were chosen to minimize Davies-Bourdin index (DBI) and was equal to 7 for Tyr-D-
Ala-(S)-α-benzyl-β-(1-piperidinyl)Ala-Asp-Val-Val-Gly-NH2 (V) and 5 for Tyr-D-Ala-(R)-α-
benzyl-β-(1-piperidinyl)Ala-Asp-Val-Val-Gly-NH2 (VI).  
 
RESULTS AND DISCUSSION 
N-Protected (R) and (S) α-benzyl-β-azido(sec-amino)alanines were synthesized from 
conveniently available β-lactones of N-Boc-(R) and (S)-α-benzylserine by ring opening with a 
sodium azide, pyrrolidine, piperidine or morpholine as nucleophile. Incorporation of α,α-
disubstituted glycines into peptides in stepwise solid-phase peptide synthesis (SPPS) is 
difficult due to their steric hindrance and lower reactivity. Our attempts to prepare DT I 
analogues by solid-phase synthesis using Boc strategy were unsuccessful. The resulting 
products, despite the use of reagents for difficult coupling and prolonged time of reaction are 
contaminated with truncated peptides (penta- and hexapeptides) due to inefficient coupling of 
α,α-disubstituted amino acids.  
The designed peptides I–VII reported here were obtained by convergent solid-phase peptide 
synthesis (CSPPS) involving the coupling of protected peptide segments on solid support (the 
fragment approach). N-Terminal tripeptides containing α,α-disubstituted glycines in position 3 
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were obtained in solution using HATU as a coupling reagent and then, after deprotection of 
the carboxyl function, were coupled with tetrapeptides on resin. N,O-Protected tripeptides 
were obtained by the stepwise peptide chain elongation in solution. (Scheme 1). The 
tetrapeptide Asp-Val-Val-Gly-NH2 was synthesized on solid phase (SPPS), following 
standard Fmoc strategy using TBTU/ HOBt for coupling reactions and piperidine 20% 
solution in DMF for Fmoc group deprotection. The final heptapeptide resins were obtained by 
segment condensation (fragments 3+4). Cleavage from the resin and removal of the protecting 
groups were carried out in one step by treatment with a mixture of TFA/H2O (95:5 by vol) (20 
mL/100 mg of peptide resin, 3.5 h at room temperature). The acid solution was concentrated 
in vacuo and the crude peptides were dissolved in water/t-butanol (1:1 by vol), lyophilized, 
and then purified by RP-HPLC. 
BocHN
OH
OR
1. CH2N2, MeOH
2. HCl/AcOEt BocHN
OCH3
OR
2. Boc-D-Ala,
HATU/HOAt,
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Scheme 1. Synthesis of N,O-protected tripeptide units 
This strategy allows for a full control and monitoring of the peptide synthesis. The cleavage 
of heptapeptides from the resin and the removal of the protecting groups was performed with 
TFA:water (95:5 by vol). All crude analogues were purified to homogeneity by RP-HPLC and 
their structures were verified by mass spectrometry. 
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The affinities of deltorphin I analogues for µ- and δ-receptors were determined by the 
radioreceptor binding assay described previously using [3H]-DAMGO and [3H]-DELT as µ- 
and δ-receptor-specific ligands, respectively. 
Table 1 shows the binding affinity of deltorphin I analogues to δ- and µ-opioid receptors in 
comparison with deltorphin I. 
Table 1. Binding affinities of deltorphin analogues I-VIII to δ and µ opioid receptors 
Peptide 
IC50 (nM) 
µ
a
  δ
b
  select.  
Tyr-D-Ala-Phe-Asp-Val-Val-Gly-NH2 (DTI) (34) 976±148  3.05±0.10c 320  
Tyr-D-Ala-(S)-α-benzyl-β-azidoAla-Asp-Val-Val-Gly-NH2 I 2473±113  655±108  3.77  
Tyr-D-Ala-(R)-α-benzyl-β-azidoAla-Asp-Val-Val-Gly-NH2 II 1272±55.5  8.8±1.0 144  
Tyr-D-Ala-(S)-α-benzyl-(1-pyrrolidinyl)Ala-Asp-Val-Val-Gly-NH2 III 1793±54.7  3178±430  0.56  
Tyr-D-Ala-(R)-α-benzyl-β-(1-pyrrolidinyl)Ala-Asp-Val-Val-Gly-NH2 IV 419±24.31  378.7±25.1 1.11 
Tyr-D-Ala-(S)-α-benzyl-β-(1-piperidinyl)Ala-Asp-Val-Val-Gly-NH2 V  2876±99.5  15.0± 1.2  192  
Tyr-D-Ala-(R)-α-benzyl-β-(1-piperidinyl)Ala-Asp-Val-Val-Gly-NH2 VI 88±3.1  669±53.5  0.13  
Tyr-D-Ala-(S)-α-benzyl-β-(4-morpholinyl)Ala-Asp-Val-Val-Gly-NH2 VII 3907± 231  2205±166  1.77  
Tyr-D-Ala-(R)-α-benzyl-β-(4-morpholinyl)Ala-Asp-Val-Val-Gly-NH2b VIII 2624±116  1373±137  1.91  
a
versus [3H]DAMGO, bveresus [3H]DELT, cversus [3H]DPDPE 
As reported in Table 1, the affinity analogues containing (R) or (S)-α-benzyl-β-azidoalanine in 
position 3 depends on the Cα chirality of α-benzyl-β-azidoalanine. The replacement of 
phenylalanine with (R)-α-benzyl-β-azidoalanine (peptide II) slightly decreases δ- and µ-
receptor affinity in comparison with parent peptide, whereas the incorporation of (S) isomer 
gives analog I, considerably less potent and δ-selective. In analogue II, the delocalized charge 
of azidomethyl group in α-benzyl-β-azidoalanine may stabilize the proposed ‘hot-dog’ 
conformation (3). The substitution of Phe3 with (R) or (S)-α-benzyl-(1-pyrrolidinyl)alanine 
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and (R) or (S)-α-benzyl-β-(4-morpholinyl) results in a loss activity and selectivity (III, IV and 
VII, VIII).  
The introduction of the conformationally restricted α-benzyl-β-(1-piperidinyl)alanine (V, VI) 
in position 3 of deltorphin I leads to changes in binding affinities to µ and δ opioid receptors, 
which are strongly affected by the configuration at Cα. The (S) isomer slightly decreases 
affinity to δ receptors and significantly to µ receptors, yielding δ-selective ligand. Changing 
the configuration of α-benzyl-β-(1-piperidinyl)alanine reverses selectivity as compared to 
deltorphin I, giving Tyr-D-Ala-(R)-α-benzyl-β-(1-piperidinyl)Ala-Asp-Val-Val-Gly-NH2 
(VI), the µ-selective ligand. In a binding assay analogue V displays a 192-fold higher 
selectivity for δ receptor, while analogue VI shows a 7.6-fold higher selectivity for µ-
receptors (over δ receptors). An NMR study was carried out to explain the opposite 
selectivities of analogues V and VI. The nuclear Overhauser effect (NOE), both in the 
laboratory and rotating frame, has been the method of choice in studying conformations of 
organic and biological molecules (25). Short linear peptides are usually characterized by high 
structural flexibility. Therefore, long-range correlations have been seldom observed in their 
NOESY/ROESY spectra. Nevertheless, one could expect peptides containing α,α 
disubstituted amino acid residue(s) to exhibit increased conformational rigidity. Complete 
assignment of 1H, proton-bearing 13C nuclei was obtained from TOCSY, ROESY and 1H/13C 
HSQC spectra.  
The representative structures of two dominant clusters of Tyr-D-Ala-(R)-α-benzyl-β-(1-
piperidinyl)Ala-Asp-Val-Val-Gly-NH2 (VI), with total population over 0.5, are shown in 
Figure 2.  
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Figure 2. Representative structures of two most populated clusters of the Tyr-D-Ala-(R)-α-
benzyl-β-(1-piperidinyl)Ala-Asp-Val-Val-Gly-NH2 (VI). Pink and blue structures have 
populations 0.269 and 0.264, respectively. The C-terminus of blue structure forms helix 
stabilized by interaction of piperidynyl with Val-6. 
The populations of two dominating clusters are nearly identical. The backbone trace of two 
structures is very similar with exception of C-terminus. The C-terminal part of the peptide can 
form helix as can be seen in Figure 2 (blue structure). The helical conformation is stabilized 
partially by hydrogen-bonds, but probably more important is hydrophobic contact between 
piperydynyl and Val6, as can be seen in Figure 3. This contacts seems to drive helix formation 
at the C-terminus.  
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Figure 3. Hydrophobic contact formed by piperidynyl and Val6 residue in Tyr-D-Ala-(R)-α-
benzyl-β-(1-piperidinyl)Ala-Asp-Val-Val-Gly-NH2 (VI) 
The Tyr-D-Ala-(S)-α-benzyl-β-(1-piperidinyl)Ala-Asp-Val-Val-Gly-NH2 (V) lacks contact 
which seems to drive helix formation and the representative structures of the most populated 
(0.3) and least populated (0.05) clusters are shown in Figure 4. These two clusters are similar 
with a major conformational difference at the C-terminus. 
 
Figure 4. Representative structures of the most populated (blue) and the least populated (pink) 
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clusters of Tyr-D-Ala-(S)-α-benzyl-β-(1-piperidinyl)Ala-Asp-Val-Val-Gly-NH2 (V). The 
peptide lacks helical conformation observed for peptide VI. 
Analogue V (Tyr-D-Ala-(S)-α-benzyl-β-(1-piperidinyl)Ala-Asp-Val-Val-Gly-NH2, Figure 4) 
lacks helical conformation observed in Tyr-D-Ala-(R)-α-benzyl-β-(1-piperidinyl)Ala-Asp-
Val-Val-Gly-NH2 (Figure 2), which can be responsible for its µ-selectivity. This confirms that 
C-terminal tail of this δ-selective deltorphin assumes an extended, rather than helix-like, 
conformation (35). These two clusters are similar with a major conformational difference at 
the C-terminus. Our studies suggest, that µ or δ selectivity appear to be forced by 
conformation adopted by the address domain.  
In conclusion, the binding assay showed, that the replacement of phenylalanine with α-
benzyl-β-azido(1-pyrrolidinyl, 1-piperidinyl, 4-morpholinyl)alanine has a strong effect on 
binding affinity. Our result supports the proposal (36) that differences between δ- and µ-
selective opioid peptides are attributable to the presence or absence of a spatial overlap 
between the N-terminal message domain and C-terminal address domain. 
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Boc-(R)-α-benzyl-β-(azido)AlaOMe ((R)-2a) 
Yield: quantitative, colorless oil, Rf= 0.85 (chloroform: methanol 95:5 v/v), [α]D20 = 133.7 [c 
= 1, CHCl3]  
1H NMR (250 MHz, CDCl3) δ: 1.49 (s, 9H, Boc); 2.98 and 3.52 (AB system, J = 13.25 Hz, 
2H, CH2Ph); 3.51 and 4.34 (system AB, J = 12.33 Hz, 2H, CH2N); 3.78 (s, 3H, OCH3); 5.49 
(broad s, 1H, NH); 7.01-7.05 (m, 2H, Ar) and 7.26-7.30 (m, 3H, Ar). 
Boc-(S)-α-benzyl-β-(azido)AlaOMe ((S)-2a) 
Yield: 98%, colorless oil, Rf = 0.85 (chloroform: methanol 95:5 v/v), [α]D25 = -132.0 [c = 1, 
CHCl3]  
1H NMR (250 MHz, CDCl3) δ: 1.49 (s, 9H, Boc); 2.97 and 3.52 (system AB, J = 13.14 Hz, 
2H, CH2Ph); 3.61 and 4.30 (system AB, J = 12.20 Hz, 2H, CH2N); 3.76 (s, 3H, OCH3); 5.49 
(s, 1H, NH); 7.01-7.07(m, 2H, Ar) and 7.25-7.30 (m, 3H, Ar). 
Boc-(R)-α-benzyl-β-(1-pyrolidinyl)AlaOMe ((R)-2b) 
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Yield: quantitative, orange oil, Rf = 0.78 (chloroform: methanol 9:1 v/v), [α]D25 = 62.1 [c = 1, 
CHCl3]  
1H NMR (250 MHZ, CDCl3) δ: 1.47 (s, 9H, Boc); 1.70-1.79 (m, 4H, N(CH2CH2)2); 2.69-2.79 
(m, 4H, N(CH2CH2)2); 3.13 and 3.14 (system AB, J = 13.71 Hz, 2H, CH2Ph); 3.46 and 3.49 
(system AB, J = 13.25 Hz, 2H, CH2N); 3.75(s, 3H, OCH3); 7.05-7.09 (m, 2H, Ar); 7.20-7.26 
(m, 3H, Ar). 
 
Boc-(S)-α-benzyl-β-(1-pyrolidinyl)AlaOMe ((S)-2b) 
Yield: 83%, orange oil, Rf  = 0.78 (chloroform: methanol 9:1 v/v), [α]D25 = -61.8 [c = 1, 
CHCl3] 
1H NMR (250 MHZ, CDCl3) δ: 1.47 (s, 9H, Boc); 1.65-1.70 (m, 4H, N(CH2CH2)2); 2.48-2.65 
(m, 4H, N(CH2CH2)2); 2.97 and 3.14 (system AB, J = 13.25 Hz, 2H, CH2Ph); 3.38 and 3.49 
(system AB, 2H, J = 13.25 Hz, CH2N); 3.76 (s, 3H, OCH3); 7.06-7.09 (m, 2H, Ar); 7.20-
7.25(m, 3H, Ar). 
 
N-Boc-(R)-α-benzylo-β-(1-piperidinyl)AlaOMe ((R)-2c) 
Yield: quantitative, orange oil, Rf = 0.50 (chloroform: methanol 9:1 v/v), [α]D25 = 56.2 [c = 1, 
CHCl3]   
1H NMR (250 MHZ, CDCl3) δ: 1.26-1.52 (m, 6H, N(CH2CH2)2CH2); 1.47 (s, 9H, Boc); 2.36-
2.50 (m, 4H, N(CH2CH2)2CH2); 2.79 and 3.32 (system AB, J = 13.71 Hz, 2H, CH2Ph); 3.08 
and 3.49 (system AB, J = 13.48 Hz, 2H, CH2N); 3.75(s, 3H, OCH3); 5.67 (s, 1H, NH); 7.04-
7.08 (m, 2H, Ar); 7.20-7.26 (m, 3H, Ar). 
 
Boc-(S)-α-benzyl-β-(1-piperidinyl)AlaOMe ((S)-2c) 
Yield:95%, orange oil, Rf = 0.50 (chloroform: methanol 9:1 v/v), [α]D25 = -55.8 [c = 1, 
CHCl3]  
1H NMR (250 MHZ, CDCl3) δ: 1.26-1.54 (m, 6H, N(CH2CH2)2CH2); 1.47 (s, 9H, Boc); 2.36-
2.50 (m, 4H, N(CH2CH2)2CH2); 2.71 and 3.37 (system AB, 2H, J = 13.71 Hz, CH2Ph); 3.08 
and 3.49 (system AB, 2H, J = 13.25 Hz, CH2N); 3.75(s, 3H, OCH3); 5.59 (s, 1H, NH); 7.04-
7.08 (m, 2H, Ar); 7.19-7.24 (m, 3H, Ar). 
 
N-Boc-(R)-α-benzyl-β-(4-morpholinyl)AlaOMe ((R)-2d) 
Yield: 78%, orange oil, Rf = 0.60 (ethyl acetate: hexane 1:1 v/v), [α]D25 = 48.5 [c = 1, CHCl3]  
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1H NMR (250 MHz, CDCl3) δ: 1.46 (s, 9H, Boc); 2.41-2.49 and 2.54-2.62 (2m, 4H, 
N(CH2CH2)2º); 2.76 and 3.42 (system AB, J = 13.71 Hz, 2H, CH2Ph); 3.02 and 3.53 (system 
AB, J = 13.48Hz, 2H, CH2N); 3.59-3.63 (m, 4H, N(CH2CH2)2º); 3.76 (s, 3H, OCH3); 5.56 (s, 
1H, NH); 7.02-7.06 (m, 2H, Ar); 7.20-7.25 (m, 3H, Ar). 
 
N-Boc-(S)-α-benzylo-β-(4-morpholinyl)AlaOMe ((S)-2d) 
Yield: 86%, orange oil, Rf = 0.60 (ethyl acetate: hexane 1:1 v/v), [α]D25 = -48.9 [c = 1, CHCl3] 
1H NMR (250 MHz, CDCl3) δ: 1.46 (s, 9H, Boc); 2.41-2.49 and 2.54-2.62 (2m, 4H, 
N(CH2CH2)2); 2.76 and 3.42 (system AB, J = 13.71 Hz, 2H, CH2Ph); 3.02 and 3.53 (system 
AB, J = 13.25Hz, 2H, CH2N); 3.58-3.62 (m, 4H, N(CH2CH2)2º); 3.76 (s, 3H, OCH3); 5.56 (s, 
1H, NH); 7.02-7.06 (m, 2H, Ar); 7.20-7.25 (m, 3H, Ar). 
N-Boc-D-Ala-(R)-α-benzyl-β-(azido)AlaOMe ((R)-3a) 
Yield: 99%, colorless oil, Rf = 0.60 (chloroform: methanol 9:1 v/v)  
1H NMR (250 MHz, CDCl3) δ: 1.33 (d, J = 7.08 Hz, 3H, CH3); 1.41 (s, 9H, Boc); 3.00 and 
3.58 (system AB, J = 13.25 Hz, 2H, CH2Ph); 3.68 and 4.44 (system AB, J = 12.33 Hz, 2H, 
CH2N); 3.78 (s, 3H, OCH3); 4.13-4.27 (m, 1H, CH); 4.96 (broad s, 1H, NH); 6.98-7.02 (m, 
2H, Ar) and 7.22-7.27 (m, 3H, Ar). 
N-Boc-D-Ala-(S)-α-benzyl-β-(azido)AlaOMe ((S)-3a) 
Yield: 95%, colorless oil, Rf = 0.58 (chloroform: methanol 9:1 v/v)  
1H NMR (250 MHz, CDCl3) δ: 1.36 (d, 3H, J = 7.08 Hz, CH3); 1.44 (s, 9H, Boc); 3.00 and 
3.59 (system AB, J = 13.48 Hz, 2H, CH2Ph); 3.73 and 4.40 (system AB, J = 12.33 Hz, 2H, 
CH2N); 3.78 (s, 3H, OCH3); 4.19 (qw, J = 7.08 Hz, 1H, CH); 4.92 (broad s, 1H, NH); 6.98-
7.02 (m, 2H, Ar) and 7.22-7.28(m, 3H, Ar). 
N-Boc-D-Ala-(R)-α-benzyl-β-(1-pyrrolidinyl)Ala Ome ((R)-3b) 
Yield: 70%, orange oil, Rf = 0.67(chloroform: methanol 9:1 v/v)  
1H NMR (250 MHZ, CDCl3) δ: 1.28 (d, J = 7.08 Hz, 3H, CH3); 1.43 (s, 9H, Boc); 1.62-1.71 
(m, 4H, N(CH2CH2)2); 2.46-2.62 (m, 4H, N(CH2CH2)2); 3.00 and 3.51 (system AB, 2H, J = 
13.14 Hz, CH2Ph); 3.20 and 3.60 (system AB, 2H J = 13.47, CH2N); 3.81 (s, 3H, OCH3); 4.13 
(qw, J = 7.08 Hz, 1H, CH); 5.00 (d, J = 7.08 Hz, 1H, NH); 7.00-7.04 (m, 2H, Ar); 7.19-7.26 
(m, 3H, Ar). 
N-Boc-D-Ala-(S)-α-benzylo-β-(1-pyrrolidinyl)AlaOMe ((S)-3b) 
Yield: 99%, orange oil, Rf = 0.67(chloroform: methanol 9:1 v/v)  
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1H NMR (250 MHZ, CDCl3) δ: 1.33 (d, J = 7.07 Hz, 3H, CH3); 1.43 (s, 9H, Boc); 1.69 (qw, J 
= 3.71 Hz, 4H, N(CH2CH2)2); 2.56-2.69 (m, 4H, N(CH2CH2)2); 3.07 and 3.50 (system AB, J 
= 13.14 Hz, 2H, CH2Ph); 3.18 and 3, 60 (system AB, 2H, J = 13.47, CH2N); 3.78 (s, 3H, 
OCH3); 4.15 (qw, J = 7.07 Hz,1H, CH); 5.01 (d, J = 7.07 Hz, 1H, NH); 7.00-7.04 (m, 2H, 
Ar); 7.18-7.23 (m, 3H, Ar). 
N-Boc-D-Ala-(R)-α-benzylo-β-(1-piperidinyl)AlaOMe ((R)-3c) 
Yield: 72%, orange oil, Rf = 0.55(chloroform: methanol 9:1 v/v)  
1H NMR (250 MHZ, CDCl3) δ: 1.27 (d, J = 7.07 Hz, 3H, CH3); 1.32-1.52 (m, 6H, 
N(CH2CH2)2CH2); 1.43 (s, 9H, Boc); 2.34-2.44 (m, 4H, N(CH2CH2)2CH2); 2.75 and 3.35 
(system AB, 2H, J = 13.71 Hz, CH2Ph); 3.18 and 3.55 (system AB, 2H, J = 13.48 Hz, CH2N); 
3.79 (s, 3H, OCH3); 4.13 (qw, J = 7.07 Hz, 1H, CH); 5.01 (d, J = 7.07 Hz, 1H, NH); 7.00-
7.04 (m, 2H, Ar); 7.18-7.23 (m, 3H, Ar). 
N-Boc-D-Ala-(S)-α-benzylo-β-(1-piperidinyl)AlaOMe ((S)-3c) 
Yield: 80%, orange oil, Rf = 0.50 (chloroform: methanol 9:1 v/v)  
1H NMR (250 MHZ, CDCl3) δ: 1.33 (d, J = 7.07 Hz, 3H, CH3); 1.37-1.50 (m, 6H, 
N(CH2CH2)2CH2); 1.43 (s, 9H, Boc); 2.29-2.51 (m, 4H, N(CH2CH2)2CH2); 2.75 and 3.42 
(system AB, 2H, J = 13.81 Hz, CH2Ph); 3.11 and 3.59 (system AB, 2H, J = 13.47 Hz, CH2N); 
3.78 (s, 3H, OCH3); 4.10-4.16 (m, 1H, CH); 4.93-4.96(m, 1H, NH) 6.98-7.02 (m, 2H, Ar); 
7.19-7.23 (m, 3H, Ar). 
N-Boc-D-Ala-(R)-α-benzylo-β-(4-morpholinyl)AlaOMe ((R)-3d) 
Yield: 77%, orange oil, Rf = 0.49 (chloroform: methanol 9:1 v/v)  
1H NMR (250 MHz, CDCl3) δ: 1.23 (d, J = 7.08 Hz, 3H, CH3); 1.41 (s, 9H, Boc); 2.37-2.46 
and 2.50-2.58 (2m, 4H, N(CH2CH2)2º); 2.79 (d, J = 13.93 Hz, 1H, HCHPh); 3.08 (d, J = 
13.71, Hz 1H, HCHN); 3.30-3.64 (m, 6H, N(CH2CH2)2º, HCHN, HCHPh); 3.80 (s, 3H, 
OCH3); 4.09 (qw, J = 7.08 Hz, 1H, CH); 4.80 (d, J=7.08 Hz, 1H, NH); 6.95-7.00(m, 2H, Ar); 
7.20-7.24 (m, 3H, Ar). 
N-Boc-D-Ala-(S)-α-benzylo-β-(4-morpholinyl)AlaOMe ((S)-3d) 
Yield: 98%, orange oil, Rf = 0.48 (chloroform: methanol 9:1 v/v)  
1H NMR (250 MHz, CDCl3) δ: 1.32 (d, J = 7.07 Hz, 3H, CH3); 1.42 (s, 9H, Boc); 2.38-2.46 
and 2.51-2.61 (2m, 4H, N(CH2CH2)2O); 2.76 (d, J = 12.46 Hz, 1H) HCHPh; 3.04 and 3.65 
(system AB, J = 13.47 Hz, 2H, CH2N); 3.56-3.60 (m, 5H, N(CH2CH2)2O, HCHPh); 3.80 (s, 
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3H, OCH3); 4.09 (qw, J = 7.07 Hz, 1H, CH); 4.80(d, J = 7.07 Hz, 1H, NH); 6.95-7.00 (m, 2H, 
Ar); 7.20-7.24 (m, 3H, Ar). 
N, O-DiBocTyr-D-Ala-(R)-α-benzyl-β-(azido)AlaOMe ((R)-4a) 
Yield: 77%, colorless oil, Rf = 0.65 (chloroform: methanol 9:1 v/v) 
1H NMR (250 MHz, CDCl3) δ: 1.22 (d, J = 6.85 Hz, 3H, CH3); 1.44 (s, 9H, Boc); 1.59 (s, 9H, 
OBoc); 3.00-3.08 (m, 2H, CH2 (Tyr) ); 3.08 and 3.54 (system AB, J = 13.48 Hz, 2H, CH2Ph); 
3.72 and 4.35 (system AB, J = 12.33 Hz, 2H, CH2N); 3.82 (s, 3H, OCH3); 4.26-4.46 (m, 2H, 
2xCH (D-Ala, Tyr)), 4.99 (broad s, 1H, NH); 6.40 (d, J = 7.77 Hz, 1H, NH); 6.90-7.02 (m, 
2H, Ar); 7.11-7.28 (m, 7H, Ar). 
N, O-DiBocTyr-D-Ala-(S)-α-benzyl-β-(azido)AlaOMe ((S)-4a) 
Yield: 98%, colorless oil, Rf = 0.62 (chloroform: methanol 9:1 v/v) 
1H NMR (250 MHz, CDCl3) δ: 1.20 (d, J = 7.08 Hz, 3H, CH3); 1.40 (s, 9H, Boc); 1.55(s, 9H, 
OBoc); 2.88-3.03 (m, 2H, CH2 (Tyr)); 3.05 and 3.51 (system AB, J = 13.48 Hz, 2H, CH2Ph); 
3.67 and 4.32 (system AB, J = 12.33 Hz, 2H, CH2N); 3.79 (s, 3H, OCH3); 4.22-4.48 (m, 2H, 
2xCH (D-Ala, Tyr); 4.97 (broad s, 1H, NH); 6.37 (d, J = 7.77 Hz, 1H, NH); 6.95-6.99 (m, 2H, 
Ar); 7.07-7.26 (m, 7H, Ar). 
N, O-DiBoc-Tyr-D-Ala-(R)-α-benzyl-β-(1-pyrrolidinyl)AlaOMe ((R)-4b) 
Yield: 76%, yellow oil, Rf = 0.55 (chloroform: methanol 9:1 v/v)  
1H NMR (250 MHZ, CDCl3) δ: 1.23 (d, J = 7.08 Hz, 3H, CH3); 1.41 (s, 9H, Boc); 1.55 (s, 
9H, OBoc); 1.62-1.71 (m, 4H, N(CH2CH2)2); 2.41-2.57 (m, 4H, N(CH2CH2)2); 2.88-3.19 (m, 
4H, CH2 (Phe, Tyr) ), 3.50-3.55 (m, 2H, CH2N); 3.78 (s, 3H, OCH3); 4.23-4.43 (m, 2H, 2xCH 
(D-Ala, Tyr) ); 6, 96-7.00 (m, 2H, Ar); 7.08-7.14 (m, 2H, Ar); 7.16-7.25 (m, 5H, Ar). 
N, O-DiBoc-Tyr-D-Ala-(S)-α-benzyl-β-(1-pyrrolidinyl)AlaOMe ((S)-4b) 
Yield: 76%, yellow oil, Rf = 0.50 (chloroform: methanol 9:1 v/v)  
1H NMR (250 MHZ, CDCl3) δ: 1.23 (d, J = 7.08 Hz, 3H, CH3); 1.40 (s, 9H, Boc); 1.55 (s, 
9H, OBoc); 1.58-1.71 (m, 4H, N(CH2CH2)2); 2.43-2.55 (m, 4H, N(CH2CH2)2); 2.87-3.20 (m, 
4H, CH2 (Phe, Tyr) ); 3.50-3.55 and 3.68-3.70 (2m, 2H, CH2N); 3.78 (s, 3H, OCH3); 4.28-
4.40 (m, 2H, 2xCH (D-Ala, Tyr)); 6.96-7.00 (m, 2H, Ar); 7.08-7.12 (m, 2H, Ar); 7.19-7.23 
(m, 5H, Ar). 
N, O-DiBoc-Tyr-D-Ala-(R)-α-benzyl-β-(1-piperidinyl)AlaOMe ((R)-4c) 
Yield: 78%, orange oil, Rf = 0.54 (chloroform: methanol 9:1 v/v) 
1H NMR (250 MHZ, CDCl3) δ: 1.21 (d, J = 7.08 Hz, 3H, CH3); 1.25-1.46 (m, 6H, 
N(CH2CH2)2CH2); 1.41 (s, 9H, Boc); 1.55 (s, 9H, OBoc); 2.31-2.40 (m, 4H, 
N(CH2CH2)2CH2); 2.74 and 3.36 (system AB, 2H, J = 13.71 Hz, CH2 (Phe)); 2.99-3.08 (m, 
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2H, CH2 (Tyr)); 3.09 and 3.52 (system AB, 2H, J = 13.48 Hz, CH2N); 3.79 (s, 3H, OCH3); 
4.23-4.43 (m, 2H, 2xCH (D-Ala, Tyr)); 6,92-6.99 (m, 2H, Ar); 7.08-7.14 (m, 2H, Ar); 7.17-
7.25 (m, 5H, Ar). 
N, O-DiBoc-Tyr-D-Ala-(S)-α-benzyl-β-(1-piperidinyl)AlaOMe ((S)-4c) 
Yield: 77%, orange oil, Rf = 0.52 (chloroform: methanol 9:1 v/v)  
1H NMR (250 MHZ, CDCl3) δ: 1.20 (d, J = 7.08 Hz, 3H, CH3); 1.23-1.39 (m, 6H, 
N(CH2CH2)2CH2); 1.44 (s, 9H, Boc); 1.58 (s, 9H, OBoc); 2.33-2.49 (m, 4H, 
N(CH2CH2)2CH2); 2.87-3.15 (m, 4H, 2x CH2 (Phe, Tyr)); 3.39 and 3.56 (system AB, 2H, J = 
13.71 Hz, CH2N); 3.80 (s, 3H, OCH)3; 4.29-4.46 (m, 2H, 2xCH (D-Ala, Tyr) ); 6, 97-7.03 (m, 
2H, Ar), 7.11-7.16 (m, 2H, Ar); 7.21-7.26 (m, 5H, Ar ) 
 
N, O-DiBocTyr-D-Ala-(R)-α-benzyl-β-(4-morpholinyl)AlaOMe((R)-4d) 
Yield: 76%, orange oil, Rf = 0.58 (chloroform: methanol 9:1 v/v)  
1H NMR (250 MHz, CDCl3) δ: 1.20 (d, J = 7.08 Hz, 3H, CH3); 1.40 (s, 9H Boc); 1.55 (s, 9H, 
OBoc); 2.35-2.51 (m, 4H, N(CH2CH2)2O); 2.76 (d, J = 13.71 Hz, 1H, HCHPh (Phe) ); 2.96-
3.04(m, 2H, CH2 (Tyr)), 3.10 (d, J = 13.48 Hz, 1H, HCHN); 3.43-3.58(m, 6H, N(CH2CH2)2O, 
HCHN, HCHPh); 3.80 (s, 3H, OCH3); 4.21-4.38(m, 2H, 2xCH(D-Ala, Tyr)); 5.05 (broad s, 
1H, NH); 6.34 (d, J = 7.77 Hz, 1H, NH); 6.93-6.98(m, 2H, Ar); 7.08-7.12 (m, 2H, Ar); 7.17-
7.24 (m, 5H, Ar) 
N, O-DiBocTyr-D-Ala-(S)-α-benzyl-β-(4-morpholinyl)AlaOMe((S)-4d) 
Yield: 85%, orange oil, Rf = 0.60 (chloroform: methanol 9:1 v/v)  
1H NMR (250 MHz, CDCl3) δ: 1.20 (d, J = 7.08 Hz, 3H, CH3); 1.41 (s, 9H) Boc; 1.55 (s, 9H) 
OBoc; 2.37-2.55 (m, 4H) N(CH2CH2)2O; 2.78 (d, J = 13.71 Hz, 1H) HCHPh (Phe); 2.96-
3.01(m, 2H) CH2 (Tyr), 3.05 (d, J = 13.48 Hz, 1H, HCHN); 3.49-3.59(m, 6H, N(CH2CH2)2O, 
HCHN, HCHPh); 3.78 (s, 3H) OCH3; 4.24-4.41(m, 2H, 2*CH, D-Ala, Tyr); 4.84-5.05 (m, 
1H, NH); 6.21 (d, 1H, NH); 6.92-6.96(m, 2H, Ar); 7.08-7.12 (m, 2H, Ar); 7.19-7.23 (m, 5H, 
Ar)  
N-BocTyr-D-Ala-(R)-α-benzyl-β-(azido)AlaOH ((R)-5a) 
Yield: quantitative, amorphous white solid, Rf = 0.42 (chloroform: methanol 8:2 v/v) 
1H NMR (250 MHz, DMSO) δ: 1.14 (d, J = 7.08 Hz, 3H, CH3); 1.29 (s, 9H, Boc); 2.57-2.70 
(m, 2H, CH2 (Tyr)); 2.75-2.80 and 2.95-3.02 (2m, 2H, CH2Ph); 3.21-3.26 and 3.72-3.80 (2m, 
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2H, CH2N); 4.08-4.10 and 4.36-4.45 (2m, 2H, 2xCH (D-Ala, Tyr)); 6.61-6.66 (m, 2H, Ar) 
6.69-7.17 (m, 4H, Ar); 7.19-7.28 (m, 3H, Ar); 9.14 (s, 1H, COOH). 
N-BocTyr-D-Ala-(S)-α-benzylo-β-(azido)AlaOH ((S)-5a) 
Yield: quantitative, amorphous white solid, Rf = 0.40 (chloroform: methanol 8:2 v/v) 
1H NMR (250 MHz, DMSO) δ: 1.14 (d, J = 7.08 Hz, 3H, CH3); 1.29 (s, 9H, Boc); 2.57-2.70 
(m, 2H, CH2 (Tyr)); 2.75-2.80 and 2.95-3.02 (2m, 2H, CH2Ph); 3.21-3.26 and 3.72-3.80 (2m, 
2H, CH2N); 4.08-4.10 and 4.36-4.45 (2m, 2H, 2xCH (D-Ala, Tyr)); 6.61-6.66 (m, 2H, Ar) 
6.69-7.17 (m, 4H, Ar); 7.19-7.28 (m, 3H, Ar); 9.14 (s, 1H) COOH. 
N-BocTyr-D-Ala-(R)-α-benzylo-β-(1-pirolidynyl)AlaOH ((R)-5b) 
Yield: 79%, amorphous white solid, Rf = 0.44 (chloroform: methanol 8:2 v/v) 
1H NMR (250 MHZ, DMSO) δ: 1.10 (d, J = 7.08 Hz, 3H, CH3); 1.28 (s, 9H, Boc); 1.84-1.96 
(m, 4H, N(CH2CH2)2); 2.39-2.74 (m, 4H, N(CH2CH2)2); 3.02-3.20 (m, 4H, 2xCH2 (Phe, 
Tyr)); 3.63 and 3.85 (2d, J=13.48 Hz, 2H, CH2N), 4.04-4.20 (m, 2H, 2xCH(D-Ala, Tyr)); 6, 
60-6.63 (m, 2H, Ar); 6.98-7.04 (m, 4H, Ar); 7.18-7.24(m, 3H, Ar); 9.16 (s, 1H, COOH). 
N-BocTyr-D-Ala-(S)-α-benzyl-β-(1-pyrrolidinyl)AlaOH ((S)-5b) 
Yield: 81%, amorphous white solid, Rf = 0.45 (chloroform: methanol 8:2 v/v) 
1H NMR (250 MHZ, DMSO) δ: 1.09 (d, J = 7.08 Hz, 3H, CH3); 1.27 (s, 9H, Boc); 1.84-1.96 
(m, 4H, N(CH2CH2)2); 2.40-2.74 (m, 4H, N(CH2CH2)2); 3.05-3.20 (m, 4H, 2xCH2 (Phe, Tyr); 
3.63 and 3.85 (2d, J=13.48 Hz, 2H, CH2N); 4.05-4.20 (m, 2H, 2xCH(D-Ala, Tyr ); 6, 60-6.63 
(m, 2H, Ar); 6.98-7.04 (m, 4H, Ar); 7.18-7.24(m, 3H, Ar); 9.16 (s, 1H, COOH). 
N-Boc-Tyr-D-Ala-(R)-α-benzyl-β-(1-piperidinyl)AlaOH ((R)-5c) 
Yield: 84%, amorphous white solid, Rf = 0.57 (chloroform: methanol 8:2 v/v) 
1H NMR (250 MHZ, DMSO) δ: 1.03 (d, J = 7.08 Hz, 3H, CH3); 1.27 (s, 9H, Boc); 1.34-1.44 
(m, 2H, N(CH2CH2)2CH2); 1.51-1.64 (m, 4H, N(CH2CH2)2CH2); 2.66-2.99 (m, 8H, 
N(CH2CH2)2CH2; 2xCH2 (Phe, Tyr)); 3.11-3.14 (m, 2H, CH2N); 4.11-4.03 (m, 2H, 2xCH (D-
Ala, Tyr)); 6.59-6.62 (m, 2H, Ar), 6.96-7.03 (m, 4H, Ar); 7.11-7.17 (m, 3H, Ar), 9.13 (s, 1H, 
COOH). 
N-Boc-Tyr-D-Ala-(S)-α-benzyl-β-(1-piperidinyl)AlaOH ((S)-5c) 
Yield: 77%, amorphous white solid, Rf = 0.59 (chloroform: methanol 8:2 v/v) 
1H NMR (250 MHZ, DMSO) δ: 1.16 (d J = 7.08 Hz, 3H, CH3); 1.28 (s, 9H, Boc); 1.36-1.48 
(m, 2H, N(CH2CH2)2CH2); 1.52-1.68 (m, 4H, N(CH2CH2)2CH2); 2.56-3.09 (m, 8H, 
N(CH2CH2)2CH2), 2xCH2 (Phe, Tyr)); 3.12-3.17 (m, 2H, CH2N); 4.04-4.19 (m, 2H, 2xCH (D-
Page 29 of 38
Chemical Biology & Drug Design - Manuscript Copy
Chemical Biology & Drug Design - Manuscript Copy
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review Only
Ala, Tyr)); 6, 91-6.97 (m, 2H, Ar), 7.01-7.04 (m, 2H, Ar); 7.09-7.29 (m, 5H, Ar), 9.17 (s, 1H, 
COOH). 
BocTyr-D-Ala-(R)-α-benzyl-β-(4-morpholinyl)AlaOH ((R)-5d) 
Yield: 90%, amorphous white solid, Rf = 0.44 (chloroform: methanol 8:2 v/v) 
1H NMR (250 MHz, CDCl3) δ: 1.17 (d, J = 7.08 Hz, 3H, CH3); 1.30 (s, 9H, Boc); 2.35-2.51 
(m, 4H, N(CH2CH2)2O); 2.96-3.04 (m, 2H, CH2(Tyr)); 3.09-3.70 (m, 8 H, CH2Ph, 
N(CH2CH2)2O, CH2N); 4.08-4.29(m, 2H, 2xCH(D-Ala, Tyr)); 6.62-6.66(m, 2H, Ar); 7.00-
7.06 (m, 4H, Ar); 7.23-7.31 (m, 3H, Ar), 9.21 (s, 1H, COOH). 
N-BocTyr-D-Ala-(S)-α-benzylo-β-(4-morpholinyl)AlaOH ((S)-5d) 
Yield: 94%, amorphous white solid, Rf = 0.45 (chloroform: methanol 8:2 v/v) 
1H NMR (250 MHz, CDCl3) δ: 1.12 (d, J = 7.08 Hz, 3H) CH3; 1.30 (s, 9H, Boc); 2.57-2.79 
(m, 4H, N(CH2CH2)2O); 2.96-3.02 (m, 2H, CH2(Tyr)), 3.09-3.63 (m, 8H, CH2Ph, 
N(CH2CH2)2O, CH2N;)); 4.08-4.29(m, 2H, 2xCH (D-Ala, Tyr)); 6.98-7.07 (m, 4H, Ar); 7.15-
7.29 (m, 5H, Ar), 9.20 (s, 1H, COOH). 
a gradient 10- 50%B over A in 20 min. 
Table 2. Structures and the physicochemical properties of the deltorphin I analogues I-VIII 
Peptide MW [g/mol] 
[M 
+H]+ 
HPLCa 
Purity% tR 
Tyr-D-Ala-(S)-α-benzyl-β-azidoAla-Asp-Val-Val-Gly-NH2 I 823.9 823.9 99 16.4 
Tyr-D-Ala-(R)-α-benzyl-β-azidoAla-Asp-Val-Val-Gly-NH2 II 823.9 824.5 99 15.0 
Tyr-D-Ala-(S)-α-benzyl-β-(1-pyrrolidinyl)Ala-Asp-Val-Val-Gly-NH2 III 852.0 853.0 99 11.3 
Tyr-D-Ala-(R)-α-benzyl-β-(1-pyrrolidinyl)Ala-Asp-Val-Val-Gly-NH2 IV 852.0 852.5 99 9.9 
Tyr-D-Ala-(S)-α-benzyl-β-(1-piperidinyl)Ala-Asp-Val-Val-Gly-NH2 V 866.0 867.1 97 10.4 
Tyr-D-Ala-(R)-α-benzyl-β-(1-piperidinyl)Ala-Asp-Val-Val-Gly-NH2 VI 866.0 867.0 97 10.5 
Tyr-D-Ala-(S)-α-benzyl-β-(4-morpholinyl)Ala-Asp-Val-Val-Gly-NH2 VII 868.0 869.0 97 9.2 
Tyr-D-Ala-(R)-α-benzyl-β-(4-morpholinyl)Ala-Asp-Val-Val-Gly-NH2 VIII 868.0 869.0 99 9.9 
 
Table 3. 1H chemical shifts (in ppm) of V and VI (AA=(S) or (R)-α-benzyl-β-(1-
piperidinyl)alanine) 
Amino acid  HN Hα Hβ Hγ Hδ Hε Hζ 
Tyr1  (S) 
(R) 
n.a. 
n.a. 
4.095 
4.111 
3.031 3.168 
3.080 3.152 
--- 
--- 
7.112 
7.146 
6.881 
6.882 
--- 
--- 
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Ala2 (S) 
(R) 
8.475 
8.455 
4.172 
4.322 
1.212 
1.189 
--- --- --- --- 
AA3 
 
(S) 
 
 
 
(R) 
8.825 
 
 
9.022 
benzyl 
piperidinyl  
benzyl 
piperidinyl  
 
3.165 3.398 
3.565 3.660 
 
3.156 3.342 
3.635 
--- 
--- 
 
--- 
--- 
7.108 
δ 2.998 3.034 
δ' 3.394 3.562 
7.139 
δ 3.030 3.544 
δ' 3.107 3.319 
7.341 
ε 1.531 1.675 
ε' 1.834 
7.361 
ε 1.611 
ε' 1.865 
7.343 
1.405 1.691 
 
n.a. 
1.692 
 
As4 (S) 
(R) 
8.606 
8.305 
4.775 
4.598 
2.788 2.869 
2.729 
--- 
--- 
--- 
--- 
--- 
--- 
--- 
--- 
Val5 (S) 
 (R) 
8.430 
8.128 
4.137 
4.083 
2.056 
2.070 
0.916 
0.858 0.899 
--- 
--- 
--- 
--- 
--- 
--- 
Val6 (S) 
(R) 
8.292 
8.171 
4.063 
4.048 
2.037 
2.024 
0.929 
0.906 
--- 
--- 
--- 
--- 
--- 
--- 
Gly
7 
(S) 
 
(R) 
8.490 
8.448 
3.864 3.916 
3.856 3.905 
--- --- --- --- --- 
C-
term  
(S) 
(R) 
7.038 
7.424 
7.029 
7.426 
--- --- --- --- --- --- 
n.a. - not assigned, AA=α-benzyl-β-(1-piperidinyl)Ala 
Table 4. 13C chemical shifts (in ppm) of V and VI (AA=(S) or (R)-α-benzyl-β-(1-
piperidinyl)alanine) 
 
Amino acid Cα Cβ Cγ Cδ Cε Cζ 
Tyr1  
 
(S) 
(R) 
57.28 
57.42 
39.00 
39.02 
n.a. 
n.a. 
133.37 
133.49 
118.67 
118.71 
n.a. 
n.a. 
Ala2   
 
(S) 
 
(R) 
52.57 
52.43 
18.52 
18.49 
--- 
--- 
--- 
--- 
--- 
--- 
--- 
--- 
AA3   
 
 
 
(S) 
 
 
(R) 
benzyl 
piperydynyl 
benzyl 
piperydynyl 
44.01 
64.98 
44.37 
65.51 
n.a. 
--- 
n.a. 
--- 
132.83 
δ 59.71  δ' 59.74 
132.88 
δ 59.33  δ' 60.34 
131.61 
ε 26.17  ε' 26.17 
131.51 
ε 26.15  ε' 26.19 
131.19 
23.30 
n.a. 
23.20 
Asp4   
 
(S) 
(R) 
n.a. 
n.a. 
39.02 
38.70 
--- 
--- 
--- 
--- 
--- 
--- 
--- 
--- 
Val5   (S) 62.70 32.73 21.03 --- --- --- 
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 (R) 62.49 32.66 20.88 21.08 --- --- --- 
Val6   
 
(S) 
(R) 
62.70 
62.65 
32.70 
32.70 
20.70 
20.68 
--- 
--- 
--- 
--- 
--- 
--- 
Gly7   
 
(S) 
(R) 
44.86 
44.82 
--- 
--- 
--- 
--- 
--- 
--- 
--- 
--- 
--- 
--- 
n.a. - not assigned, AA=α-benzyl-β-(1-piperidinyl)Ala 
Table 5. 15N chemical shifts (in ppm) of V and VI (AA=(S) or (R)-α-benzyl-β-(1-
piperidinyl)alanine) 
 
Amino acid N 
Ala2 (S) 
(R) 
127.77 
127.91 
AA3 (S) 
R 
142.54 
126.47 
Asp4 (S) 
(R) 
116.20 
116.85 
Val5 (S) 
(R) 
122.31 
123.18 
Val6 (S) 
(R) 
125.00 
124.38 
Gly7 (S) 
(R) 
114.21 
113.98 
C-term (S) 
(R) 
107.18 
107.18 
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Figure 2. Representative structures of two most populated clusters of the Tyr-D-Ala-(R)-α-
benzyl-β-(1-piperidinyl)Ala-Asp-Val-Val-Gly-NH2 (VI). Pink and blue structures have 
populations 0.269 and 0.264, respectively. The C-terminus of blue structure forms helix 
stabilized by interaction of piperidynyl with Val-6. 
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Figure 3. Hydrophobic contact formed by piperidynyl and Val
6
 residue in Tyr-D-Ala-(R)-α-
benzyl-β-(1-piperidinyl)Ala-Asp-Val-Val-Gly-NH2 (VI) 
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Figure 4. Representative structures of the most populated (blue) and the least populated (pink) 
clusters of Tyr-D-Ala-(S)-α-benzyl-β-(1-piperidinyl)Ala-Asp-Val-Val-Gly-NH2 (V). The 
peptide lacks helical conformation observed for peptide VI. 
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Synthesis, biological activity and NMR-based structural studies of deltorphin I 
analogues modified in message domain with a new α,α-disubstituted glycines† 
 
Anika Lasota
a, Oliwia Frączaka, Adriana Muchowskab, Michał Nowakowskic, Maciej 
Maciejczyk
d
, Andrzej Ejchart
e
, Aleksandra Olma
a*
 
 
Table 1. Binding affinities of deltorphin analogues I-VIII to δ and μ opioid receptors 
Peptide 
IC50 (nM) 
μa  δb  select.  
Tyr-D-Ala-Phe-Asp-Val-Val-Gly-NH2 (DTI)
 
(34) 976±148  3.05±0.10c 320  
Tyr-D-Ala-(S)-α-benzyl-β-azidoAla-Asp-Val-Val-Gly-NH2 I 2473±113  655±108  3.77  
Tyr-D-Ala-(R)-α-benzyl-β-azidoAla-Asp-Val-Val-Gly-NH2 II 1272±55.5  8.8±1.0 144  
Tyr-D-Ala-(S)-α-benzyl-(1-pyrrolidinyl)Ala-Asp-Val-Val-Gly-NH2 III 1793±54.7  3178±430  0.56  
Tyr-D-Ala-(R)-α-benzyl-β-(1-pyrrolidinyl)Ala-Asp-Val-Val-Gly-NH2 IV 419±24.31  378.7±25.1 1.11 
Tyr-D-Ala-(S)-α-benzyl-β-(1-piperidinyl)Ala-Asp-Val-Val-Gly-NH2 V  2876±99.5  15.0± 1.2  192  
Tyr-D-Ala-(R)-α-benzyl-β-(1-piperidinyl)Ala-Asp-Val-Val-Gly-NH2 VI 88±3.1  669±53.5  0.13  
Tyr-D-Ala-(S)-α-benzyl-β-(4-morpholinyl)Ala-Asp-Val-Val-Gly-NH2 VII 3907± 231  2205±166  1.77  
Tyr-D-Ala-(R)-α-benzyl-β-(4-morpholinyl)Ala-Asp-Val-Val-Gly-NH2
b
 VIII 2624±116  1373±137  1.91  
a
versus [
3
H]DAMGO, 
b
veresus [
3
H]DELT, 
c
versus [
3
H]DPDPE 
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